Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets [Yahoo! Finance]
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Castle Biosciences is back in focus as some analysts move price targets from the mid $30s to around $52, while at least one fair value view at $48.5 remains unchanged. These shifts are being tied directly to preliminary 2025 revenue disclosures and refreshed 2026 revenue estimates, with differing opinions on how much the new data supports higher targets. As you read on, you will see how these evolving views fit together and what to watch next as the narrative develops. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Castle Biosciences. What Wall Street Has Been Saying ?? Bullish Takeaways Lake Street lifted its Castle Biosciences price target to $52 from $35 after the company shared preliminary 2025 revenue figures, signaling greater confidence in how future 2026 revenue estimates support a higher valuation framework. Lake Street indicated that its updated target now leans on 2026 revenue estimates, which
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript [Seeking Alpha]Seeking Alpha
- Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk [Yahoo! Finance]Yahoo! Finance
- Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB [Yahoo! Finance]Yahoo! Finance
- Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNBGlobeNewswire
- SciBase: Interim report [Yahoo! Finance]Yahoo! Finance
CSTL
Earnings
- 2/26/26 - Beat
CSTL
Sec Filings
- 3/19/26 - Form 4
- 3/17/26 - Form 4
- 3/16/26 - Form 4
- CSTL's page on the SEC website